1,040 Shares in United Therapeutics Corporation $UTHR Bought by Fideuram Asset Management Ireland dac

Fideuram Asset Management Ireland dac bought a new position in United Therapeutics Corporation (NASDAQ:UTHR) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 1,040 shares of the biotechnology company’s stock, valued at approximately $473,000.

A number of other institutional investors also recently bought and sold shares of the stock. Clearstead Advisors LLC raised its holdings in United Therapeutics by 8.9% in the 3rd quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 23 shares during the period. Independent Advisor Alliance raised its holdings in United Therapeutics by 3.3% in the 4th quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock worth $406,000 after purchasing an additional 27 shares during the period. Bessemer Group Inc. raised its holdings in United Therapeutics by 2.6% in the 3rd quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company’s stock worth $472,000 after purchasing an additional 28 shares during the period. Signaturefd LLC raised its holdings in United Therapeutics by 4.1% in the 4th quarter. Signaturefd LLC now owns 896 shares of the biotechnology company’s stock worth $437,000 after purchasing an additional 35 shares during the period. Finally, WealthCollab LLC raised its holdings in United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares during the period. 94.08% of the stock is owned by institutional investors.

United Therapeutics Stock Down 0.9%

Shares of United Therapeutics stock opened at $556.82 on Friday. The firm has a market cap of $23.64 billion, a price-to-earnings ratio of 20.55, a PEG ratio of 1.81 and a beta of 0.60. The business has a 50-day moving average price of $566.51 and a 200-day moving average price of $515.84. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The firm had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $6.63 EPS. On average, equities analysts expect that United Therapeutics Corporation will post 26.92 EPS for the current fiscal year.

Insider Activity at United Therapeutics

In related news, CFO James Edgemond sold 10,000 shares of the stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $527.48, for a total value of $5,274,800.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at approximately $9,956,712.48. This trade represents a 34.63% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders have sold 601,473 shares of company stock valued at $337,090,644. 8.60% of the stock is currently owned by company insiders.

United Therapeutics News Roundup

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics is still drawing support from bullish analyst coverage, including recent higher price targets and buy/overweight ratings, which suggests Wall Street remains constructive on the long-term outlook.
• Positive Sentiment: The company continues to highlight clinical and business-development catalysts, including its PHINDER screening study, xenokidney/EXTEND trial progress, and a planned presentation at the Jefferies Global Healthcare Conference, all of which help keep the growth story visible to investors. Article Title Article Title
• Neutral Sentiment: A separate article referenced United Therapeutics in a broader mid-cap stock discussion, but it did not appear to contain company-specific new information likely to move the stock.
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares and CFO James Edgemond sold 10,000 shares this week. Multiple insider sales can weigh on sentiment, especially when they come soon after a disappointing earnings report. Article Title Article Title
• Negative Sentiment: The company’s most recent quarterly results missed estimates on both EPS and revenue, leaving investors with an ongoing fundamental overhang despite strong profitability metrics.

Analyst Ratings Changes

A number of brokerages have issued reports on UTHR. UBS Group increased their price target on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. Bank of America increased their price target on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 31st. Royal Bank Of Canada cut their price target on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Finally, Cantor Fitzgerald increased their price target on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $619.42.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.